The Aptamarker Platform

Background:

By translating information on protein abundance to information on DNA abundance High-Plex proteomics brings deeper analysis than transcriptomics on a protein level. Pioneers like Olink and Somalogic have been leaders in building a future based on protein abundance.

There are, however, weaknesses in the approaches that they are using. The bottom-up approach of building panels of probes for individual proteins is powerful, but presents the following constraints.

• Inability to characterize changes to proteins such as post-translational modifications and cleavage events.
• Validation concerns surrounding dissimilarity in performance of probes individually and in conjunction with other probes
• Limitation to reference set on human proteins
• Need for new and expensive equipment
• Accessibility to probes for Dx applications.

The Aptamarker platform:

At NeoVentures Biotechnology Europe (Paris) we have developed a top-down approach to High-Plex proteomics that overcomes the constraints listed above. Our top-down approach is based on our innovative system to applying the same 16.8 million aptamer sequences to different samples. We do not need to build a panel of probes from the bottom-up. We are characterizing the performance of our deep library of probes against samples where protein abundance has been characterized.

This approach solves the problems listed above as follows.

• We have redundancy in terms of probes/protein binding. This enables us to detect and characterize post-translational changes.
• Our probes are characterized within a library rather than individually, so their performance along with other probes is implicit to how we build information on them. We also validate performance of individual probes against targeted proteins through qPCR analysis.
• Our library is completely agnostic in terms of what species it is applied to. We can work with human or other animal samples.
• Our entire approach can be performed with existing equipment in any molecular biology laboratory. Our patented FRELEX selection method simplifies the process of quantification of aptamers by relying on a single microcentrifugation step to separate bound from unbound aptamers.
• With 16.8 million probes our business model in able to provide a path to Dx applications.

To learn more about the Aptamarker platform and how it can help you extend the knowledge from your existing Olink or Somascan data contact us at info@neoventures-eu.com

You can characterize post-translational changes to candidate biomarkers, or you can rebuild your database so you can proceed to Dx applications.